WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2010033219) PROTEASE INHIBITORS HAVING ENHANCED FEATURES
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2010/033219    International Application No.:    PCT/US2009/005208
Publication Date: 25.03.2010 International Filing Date: 17.09.2009
IPC:
A61K 47/48 (2006.01), A61P 31/18 (2006.01)
Applicants: NEKTAR THERAPEUTICS [US/US]; 201 Industrial Road San Carlos, California 94070 (US) (For All Designated States Except US).
JUDE-FISHBURN, C., Simone [GB/US]; (US) (For US Only).
VANDERVEEN, Laurie, Anne [US/US]; (US) (For US Only).
RILEY, Timothy A. [US/US]; (US) (For US Only)
Inventors: JUDE-FISHBURN, C., Simone; (US).
VANDERVEEN, Laurie, Anne; (US).
RILEY, Timothy A.; (US)
Agent: DESAI, Naishadh; Nektar Therapeutics 201 Industrial Road San Carlos, California 94070 (US)
Priority Data:
61/192,417 17.09.2008 US
61/192,439 17.09.2008 US
61/192,459 17.09.2008 US
61/198,934 12.11.2008 US
Title (EN) PROTEASE INHIBITORS HAVING ENHANCED FEATURES
(FR) INHIBITEURS DE PROTÉASES AYANT DES PROPRIÉTÉS AMÉLIORÉES
Abstract: front page image
(EN)Provided herein (among other things) are protease inhibitor compounds having enhanced features, along with methods for administering such compounds. For example, the subject compounds can be administered without concomitant administration of a CYP3A4 inhibitor, have increased therapeutic index and/or increased potency, and are low-resistance inducing in nature. Exemplary potent HIV protease inhibitors are mono-m-PEG3-atazanavir, mPEGn-N-darunavir (wherein n is 3 or 5), mPEGn-NHCO-saquinavir (wherein n is 5 or 7), and di-mPEG3-atazanavir.
(FR)Cette invention concerne (entre autres) des composés inhibiteurs de protéases ayant des propriétés améliorées, ainsi que des procédés pour administrer ces composés. Par exemple, les présents composés peuvent être administrés sans administration concomitante d'un inhibiteur de CYP3A4, ont un index thérapeutique supérieur et/ou un pouvoir accru, et induisent une basse résistance par nature.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)